» Articles » PMID: 27538882

Enhancing Oral Absorption of β-Lapachone: Progress Till Date

Overview
Date 2016 Aug 20
PMID 27538882
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

β-Lapachone is a naphthoquinone with high and diverse biological activity. It is useful to treat several pathologies, in particular cancer due to its ability to induce selective apoptosis in tumoral cells. Despite its advantages, β-lapachone's clinical applications are limited by its low solubility in biological fluids and its low specific distribution pattern. In the last decade various formulation strategies have been designed and developed in order to overcome these limitations and to make feasible its wide therapeutic use. The most relevant strategies for oral administration have been focused on the improvement of its solubility in order to increase β-lapachone oral bioavailability. The use of cyclodextrins or the inclusion of the active substance in micelles and microparticles has demonstrated to be successful approaches. For topical and local application temperature-sensitive hydrogels have been developed to achieve high target concentrations. Polymeric micelles administrated subcutaneously have proved to be a long-lasting circulating system and to increase accumulation in tumor tissue making them an interesting formulation strategy.

Citing Articles

β-Lapachone Exerts Hypnotic Effects via Adenosine A Receptor in Mice.

Lee D, Jee H, Jung Y Biomol Ther (Seoul). 2024; 32(5):531-539.

PMID: 39164983 PMC: 11392670. DOI: 10.4062/biomolther.2024.106.


The possibility of low isomerization of β-lapachone in the human body.

Lee K, Gwon M, Lee H, Seong S, Yoon Y Transl Clin Pharmacol. 2021; 29(3):160-170.

PMID: 34621708 PMC: 8492396. DOI: 10.12793/tcp.2021.29.e16.


β-Lapachone Induces Acute Oxidative Stress in Rat Primary Astrocyte Cultures that is Terminated by the NQO1-Inhibitor Dicoumarol.

Steinmeier J, Kube S, Karger G, Ehrke E, Dringen R Neurochem Res. 2020; 45(10):2442-2455.

PMID: 32789798 PMC: 7511478. DOI: 10.1007/s11064-020-03104-0.


Pharmacokinetics and derivation of an anticancer dosing regimen for the novel anti-cancer agent isobutyl-deoxynyboquinone (IB-DNQ), a NQO1 bioactivatable molecule, in the domestic felid species.

Lundberg A, Francis J, Pajak M, Parkinson E, Wycislo K, Rosol T Invest New Drugs. 2016; 35(2):134-144.

PMID: 27975234 DOI: 10.1007/s10637-016-0414-z.

References
1.
Chakrabarti G, Moore Z, Luo X, Ilcheva M, Ali A, Padanad M . Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachone. Cancer Metab. 2015; 3:12. PMC: 4601138. DOI: 10.1186/s40170-015-0137-1. View

2.
Nasongkla N, Wiedmann A, Bruening A, Beman M, Ray D, Bornmann W . Enhancement of solubility and bioavailability of beta-lapachone using cyclodextrin inclusion complexes. Pharm Res. 2003; 20(10):1626-33. DOI: 10.1023/a:1026143519395. View

3.
Park E, Min K, Lee T, Yoo Y, Kim Y, Kwon T . β-Lapachone induces programmed necrosis through the RIP1-PARP-AIF-dependent pathway in human hepatocellular carcinoma SK-Hep1 cells. Cell Death Dis. 2014; 5:e1230. PMC: 4047891. DOI: 10.1038/cddis.2014.202. View

4.
Siegel D, Franklin W, Ross D . Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors. Clin Cancer Res. 1998; 4(9):2065-70. View

5.
Park S, Kim J, Kim K, Jeong M, Park H, Park B . Beta-lapachone inhibits pathological retinal neovascularization in oxygen-induced retinopathy via regulation of HIF-1α. J Cell Mol Med. 2014; 18(5):875-84. PMC: 4119393. DOI: 10.1111/jcmm.12235. View